|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | AM-Pharma |
|---|---|
| Information provided by: | AM-Pharma |
| ClinicalTrials.gov Identifier: | NCT00511186 |
Purpose
The purpose of this study is to investigate the safety and tolerability of AP in sepsis patients with renal failure and to investigate the effect of AP on inflammatory and clinical parameters in sepsis patients with renal failure.
| Condition | Intervention | Phase |
|---|---|---|
|
Sepsis Bacterial Infections and Mycoses |
Drug: Placebo Drug: BIAP |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Phase-IIa, Double-blind, Randomized, Placebo-controlled Study on the Safety and Early Efficacy of Alkaline Phosphatase in Sepsis Patients With Renal Failure |
| Enrollment: | 36 |
| Study Start Date: | May 2008 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Bovine Intestinal Alkaline Phosphatase (BIAP)
|
Drug: BIAP
AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
Other Names:
|
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo
placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
Other Name: Placebo
|
RATIONALE FOR THE STUDY
A previous clinical study conducted in centers in The Netherlands and Belgium have shown a substantial clinical benefit of AP treatment in patients with sepsis and associated acute renal failure (see Introduction above). The latter results require confirmation in a prospective study, as the current subject of this Protocol.
Choice of Drugs
The proposed study medication (AP) is identical to the study medication used in the previous clinical study in sepsis patients with single or multiple end-organ failure. Since there is no current proven treatment for these patients, the controls (as in previous studies) is placebo.
Choice of patient population
The aim is to enroll a maximum of 26 patients positive for sepsis with an APACHE score of ≥20 and ≤28 (determined within 24 hours of entry), and who will be analyzed on an intention to treat (ITT) basis.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Two out of four SIRS criteria of systemic inflammation, existing for less than 24 hours after admission in the intensive care unit, as follows:
Acute renal failure, defined as
Exclusion Criteria:
Contacts and Locations| Belgium | |
| University Medical Center Antwerp (UZA) | |
| Antwerp, Belgium | |
| Universitair Ziekenhuis Brussel | |
| Brussels, Belgium | |
| Cliniques Universitaires Saint Luc-UCL | |
| Brussels, Belgium | |
| ULB Hopital Erasme | |
| Brussels, Belgium | |
| Netherlands | |
| UMC Nijmegen University Medical Center St Radboud | |
| Nijmegen, Gelderland, Netherlands, 6500 HB | |
| Isala Clinics | |
| Zwolle, Overijssel, Netherlands, 8011 JW | |
| Jeroen Bosch Ziekenhuis lokatie GZG | |
| 's-Hertogenbosch, Netherlands | |
| VU University Medical Center | |
| Amsterdam, Netherlands | |
| Canisius Wilhelmina Ziekenhuis | |
| Nijmegen, Netherlands | |
| Principal Investigator: | Professor J G van der Hoeven, MD, PhD | University Medical Center St Radboud, Nijmegen, The Netherlands |
More Information
| Responsible Party: | Dr J Arend, MD, AM-Pharma |
| ClinicalTrials.gov Identifier: | NCT00511186 History of Changes |
| Other Study ID Numbers: | AP REN 01-01 |
| Study First Received: | August 2, 2007 |
| Last Updated: | January 5, 2010 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
Sepsis Alkaline Phosphatase inflammation infection renal failure |
|
Bacterial Infections Mycoses Renal Insufficiency Sepsis Toxemia Kidney Diseases |
Urologic Diseases Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |